Brief: Biocartis H1 Operating Loss Widens To 33.1 Million Euros

Biocartis NV

02/09/2021 06:12

Sept 2 (Reuters) - Biocartis Group NV  BCART.BR :
    * BIOCARTIS ANNOUNCES H1 2021 RESULTS
    * 156K COMMERCIAL IDYLLA CARTRIDGES SOLD, ALMOST TWICE AS
HIGH AS
IN H1 2020 (+96%) AND 189 NEW IDYLLA™PLACEMENTS IN H1 2021
    * OUTLOOK 40% CARTRIDGE GROWTH STILL IN REACH FOLLOWING
SUCCESSFUL
MITIGATION OF FIRE INCIDENT, BUT STILL SUBJECT TO FULL RESTART
OF ML2 LINE BY 2ND HALF SEPTEMBER
    * H1 TOTAL OPERATING INCOME EUR 23.1 MILLION VERSUS EUR 17.6
MILLION YEAR AGO
    * H1 OPERATING LOSS EUR 33.1 MILLION VERSUS LOSS EUR 26.4
MILLION
YEAR AGO
    * H1 NET LOSS EUR 37.3 MILLION VERSUS EUR 31.6 MILLION YEAR
AGO
    * NET CASH OUTFLOW FROM OPERATING AND INVESTING ACTIVITIES
AMOUNTED TO EUR 35.8M IN H1 2021 COMPARED TO EUR 25.6M IN H1
2020
    * CASH POSITION: TARGETING AT LEAST EUR 50M CASH POSITION AT
YEAR-END, PROVIDED TIMELY COLLECTION OF INSURANCE CLAIMS RELATED
TO FIRE INCIDENT
    * LUNG CANCER: LAUNCH OF IDYLLA™ EGFR-BRAF+ MUTATION ASSAY
IS
BEING SUSPENDED AWAITING COMPLETION OF SIMPLIFIED,
COST-EFFICIENT CARTRIDGE CONCEPT
    * BREAST CANCER: LAUNCH OF IDYLLA™ ABC (ADVANCED BREAST
CANCER)
ASSAY IN COLLABORATION WITH LIFEARC IS EXPECTED IN H2 2022
    * TIMING OF EMERGENCY USE AUTHORIZATION ('EUA') SUBMISSION
TO US
FDA FOR IDYLLA™ SARS-COV-2/FLU/RSV PANEL TO BE DECIDED

Source text for Eikon:  ID:nGNEbM0RMt 
Further company coverage:  BCART.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))